Veracyte announces study results for thyroid cancer classifier

Updated Jul 22, 2022
2019 04 29 20 27 3521 Thyroid 400

Veracyte announced Wednesday that its thyroid cancer genomic test showed high sensitivity and specificity in detecting medullary thyroid cancer (MTC) among preoperative thyroid nodule fine needle aspiration biopsy samples in a study published online in Thyroid.

The results suggest that the firm's RNA sequencing-based medullary thyroid cancer classifier, Afirma, may enable more timely diagnosis of this rare, aggressive form of thyroid cancer, Veracyte said.

To assess the test, investigators evaluated a blinded cohort of 211 preoperative thyroid fine needle aspiration samples with subsequent surgical pathology, including 21 MTC samples and 190 non-MTC samples that included both benign and malignant thyroid lesions. The classifier accurately identified all 21 MTC cases with 100% sensitivity and all 190 non-MTC cases with 100% specificity.

Page 1 of 1